Scientific/Clinical Member Nominations are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV

Virtual meeting for panel members
Date

Source ClinicalInfo

The HHS Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV (or the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates with expertise and current engagement in the: 

  • clinical use of antiretrovirals in infants and children, including in neonates and infants exposed to HIV 

  • clinical pharmacology of antiretrovirals in neonates (premature and full term), infants, and children 

  • implementation and dissemination science involving the use of antiretrovirals in infants and children 

Individuals who served as Panel members in the past are welcome to reapply. 
 
Panel members critically evaluate new information and prepare guidelines revisions. Candidates should be recognized experts in their areas of interest. Successful candidates will serve a 3-year term beginning January 2027, with potential for reappointment for an additional term. 
 
The Panel is a Working Group of the Office of AIDS Research Advisory Council of the National Institutes of Health. The Panel is composed of approximately 34 members who are clinicians, researchers, academics, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via videoconferencing to review and critically evaluate emerging scientific data relating to antiretroviral therapy in children and revise the Guidelines for Use of Antiretroviral Agents in Pediatric HIV Infection. In addition, an Antiretroviral Subgroup meets monthly. Those with pharmacologic expertise would be expected to attend both meetings. Panel members are not financially compensated for their time commitment.  
 
Nominations should include a curriculum vitae and a letter of interest or a letter of nomination with specific reference to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Segun Adeyemi, Guidelines Coordinator, at [email protected] no later than October 31, 2026.